Optimind Pharma | Psychedelic Enhanced Psychotherapy
  • The Treatment
  • About Us
    • Overview
    • Our Team
  • R&D
  • Investors
  • Get in Touch
Select Page

Optimind Acquires MindSetting Institute to Integrate Three-Pronged Approach to its Business and Become Industry Leader in Psychedelic Enhanced Psychotherapy

by optimindpharma | Sep 20, 2022 | Press Releases

Optimind looks to accelerate the adoption of the MindSetting(TM) TRIP Protocol for ketamine-assisted therapy and other psychedelic enhanced psychotherapy modalities.     Toronto, Ontario–(Newsfile Corp. – September 20, 2022) – Optimind Pharma...

Optimind Provides Update on Health Canada’s Dealer License under Joint-Venture with Manitari Pharma

by optimindpharma | Aug 10, 2022 | Press Releases

Optimind Provides Update on Health Canada’s Dealer License under Joint-Venture with Manitari Pharma Manitari Pharma received approval to begin construction of Security Level 3 safe + grow rooms   Manitari Pharma is one step closer to obtaining Controlled Substances...

Optimind Pharma Commences Trading on the CSE Under Ticker Symbol OMND

by optimindpharma | Aug 4, 2022 | Press Releases

Optimind Pharma Commences Trading on the CSE Under Ticker Symbol OMND TORONTO – Optimind Pharma Corp. (CSE:OMND (“Optimind” or the “Company”) today announced its commencement of trading on the CSE (Canadian Securities Exchange) under ticker symbol “OMND”. Optimind...

Optimind Pharma Announces Closing of Reverse Takeover Transaction

by optimindpharma | Aug 2, 2022 | Press Releases

Optimind Pharma Announces Closing of Reverse Takeover Transaction Toronto, Ontario–(Newsfile Corp. – July 29, 2022) – Optimind Pharma Corp. (“Optimind” or the “Company”) announces the successful closing of its previously...

Recent Posts

  • Optimind Acquires MindSetting Institute to Integrate Three-Pronged Approach to its Business and Become Industry Leader in Psychedelic Enhanced Psychotherapy
  • Optimind Provides Update on Health Canada’s Dealer License under Joint-Venture with Manitari Pharma
  • Optimind Pharma Commences Trading on the CSE Under Ticker Symbol OMND
  • Optimind Pharma Announces Closing of Reverse Takeover Transaction

Recent Comments

    • Follow
    • Follow
    • Follow

     

    The Treatment

    Research & Development

    About Us

    Investors

    Contact Us

    All Rights Reserved © 2021

    Stay up to date

    Subscribe to our newsletter to stay in the loop and recieve updates directly from Optimind.

    Thank you for signing up to our newsletter. Please check your inbox and mark us as a trusted contact to ensure our mail never goes to your spam folder.

    Subscribe

    All Rights Reserved © 2021